FDA
approval
· 2016-11-04
FDA Approved: ALECENSA — Supplemental Application (Genentech, Inc.)
Summary
The FDA approved a supplemental application for ALECENSA (alectinib hydrochloride) to update the label for its use in ALK-positive non-small cell lung cancer, r…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for ALECENSA (ALECTINIB HYDROCHLORIDE)